Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2008

View Archived Issues

MDV-3100 well tolerated, reduces PSA in castration-resistant prostate cancer patients

In vitro and in vivo activity against hepatocellular cancer seen with CUDC-101

PDL BioPharma reports development of anti-TweakR antibody with antitumor activity

Serenex describes discovery of SNX-5422, an Hsp90 inhibitor in phase I development

F-14512 activity depends on polyamine transport system status of tumors

Positive preclinical data of Palomid-529 in models of ocular disorders

Evotec completes acquisition of Renovis

Corcept reports promising results from human microdosing study of CORT-108297

Epix initiates phase IIb clinical trial of PRX-03140 in combination with Aricept

NanoViricides reports initial results from mouse studies of HivCide-I for HIV/AIDS

Antennapedia Trojan peptide-p21 fusion protein inhibits tumor cell growth

Bayer Schering Pharma to market new low-dose oral contraceptive in Europe

TG-100801's clinical evaluation discontinued due to phase IIa results

Catalyst selects second-generation factor VIIa variant as candidate for hemophilia

DiaMedica enrolls final patient in phase DM-83 clinical trial

FDA accepts for review Cinryze complete response submission

QRxPharma releases successful phase III study results for Q-8003-IR

Cadence completes full enrollment in phase III CLIRS clincial trial of Omigard

FDA Advisory Committee recommends against approval of Fentora expanded label

Genentech initiates phase II clinical trial of GDC-0449 in metastatic colorectal cancer

Novel agents for treating autoimmune diseases disclosed in recent Pharmacopeia patents

Targacept designates neuronal nicotinic receptor drug in smoking cessation program

Recent patents claim novel therapeutic agents for psychosis, depression and anxiety

LLS and MannKind enter agreement to develop targeted tyrosine kinase inhibitor

Glenmark launches topical antifungal cream Onabet in India

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...